Bio Medica Laboratories SME IPO GMP Today

GMP for Bio Medica Laboratories SME started at Rs 0 on 17 May 2026 and stood at Rs 0 on 26 May 2026. The sharpest single-day jump was from Rs 0 on 20 May 2026 to Rs 3 on 21 May 2026. GMP has moved in both directions during the tracked period. That often means sentiment is unsettled and the final listing price is harder to predict.

Based on today's GMP, Bio Medica Laboratories SME IPO listing price estimate is Rs 130.00 per share (issue price Rs 139.00 + GMP Rs -9.00).

Actual listing price will be known on 29 May 2026 when the stock lists on NSE/BSE.

Negative GMP suggests the unofficial market expects listing below the issue price. Treat this as a warning sign and read subscription numbers before deciding.

GMP is unofficial. Listing gain can differ on listing day.

GMP and subscription numbers often move together. When institutional and HNI demand is strong, grey market participants usually price in a higher premium. Current overall subscription for Bio Medica Laboratories SME is 2.31x. Compare this with the GMP trend to see if demand aligns. The GMP move around 21 May 2026 may reflect how the market reacted once the subscription window activity picked up after 21 May 2026.

See live figures on the Bio Medica Laboratories SME IPO Subscription Status page.

Bio Medica Laboratories SME IPO full details (financials, peers, review).

Bio Medica Laboratories Limited, incorporated in 2015, is an Indian pharmaceutical manufacturer specializing in parenteral formulations. The company develops and contract-manufactures a wide range of ethical drugs, generic medicines, and over-the-counter (OTC) products in the form of liquid and dry powder injectables. Operating entirely on a B2B contract manufacturing model, it designs multi-dose and single-dose injectables for both human and veterinary applications. The company runs two specialized production facilities in Indore, Madhya Pradesh, certified for Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).